Literature DB >> 9153317

Efficient in vitro inhibition of HIV-1 gag reverse transcription by peptide nucleic acid (PNA) at minimal ratios of PNA/RNA.

U Koppelhus1, V Zachar, P E Nielsen, X Liu, J Eugen-Olsen, P Ebbesen.   

Abstract

We have tested the inhibitory potential of peptide nucleic acid (PNA) on in vitro reverse transcription of the HIV-1 gag gene. PNA was designed to target different regions of the HIV-1 gag gene and the effect on reverse transcription by HIV-1, MMLV and AMV reverse transcriptases (RTs) was investigated. We found that a bis-PNA (parallel antisense 10mer linked to antiparallel antisense 10mer) was superior to both the parallel antisense 10mer and antiparallel antisense 10mer in inhibiting reverse transcription of the gene, thus indicating triplex formation at the target sequence. A complete arrest of reverse transcription was obtained at approximately 6-fold molar excess of the bis-PNA with respect to the gag RNA. At this molar ratio we found no effect on in vitro translation of gag RNA. A 15mer duplex-forming PNA was also found to inhibit reverse transcription at very low molar ratios of PNA/ gag RNA. Specificity of the inhibition of reverse transcription by PNA was confirmed by RNA sequencing, which revealed that all tested RTs were stopped by the PNA/RNA complex at the predicted site. We propose that the effect of PNA is exclusively due to steric hindrance, as we found no signs of RNA degradation that would indicate PNA-mediated RNase H activation of the tested RTs. In conclusion, PNA appears to have a potential to become a specific and efficient inhibitor of reverse transcription in vivo , provided sufficient intracellular levels are achievable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153317      PMCID: PMC146729          DOI: 10.1093/nar/25.11.2167

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  25 in total

Review 1.  Oligodeoxynucleotides as antisense inhibitors of gene expression.

Authors:  M K Ghosh; J S Cohen
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1992

Review 2.  Phosphorothioate oligodeoxynucleotides--anti-sense inhibitors of gene expression?

Authors:  C A Stein; J L Tonkinson; L Yakubov
Journal:  Pharmacol Ther       Date:  1991-12       Impact factor: 12.310

3.  Antisense and antigene properties of peptide nucleic acids.

Authors:  J C Hanvey; N J Peffer; J E Bisi; S A Thomson; R Cadilla; J A Josey; D J Ricca; C F Hassman; M A Bonham; K G Au
Journal:  Science       Date:  1992-11-27       Impact factor: 47.728

4.  Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease.

Authors:  S Erickson-Viitanen; J Manfredi; P Viitanen; D E Tribe; R Tritch; C A Hutchison; D D Loeb; R Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  1989-12       Impact factor: 2.205

5.  Endoribonucleolytic cleavage of RNA: oligodeoxynucleotide hybrids by the ribonuclease H activity of HIV-1 reverse transcriptase.

Authors:  L R Dudding; A Harington; V Mizrahi
Journal:  Biochem Biophys Res Commun       Date:  1990-02-28       Impact factor: 3.575

6.  Human transformed trophoblast-derived cells lacking CD4 receptor exhibit restricted permissiveness for human immunodeficiency virus type 1.

Authors:  V Zachar; B Spire; I Hirsch; J C Chermann; P Ebbesen
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

7.  Mechanisms of the inhibition of reverse transcription by unmodified and modified antisense oligonucleotides.

Authors:  T Hatta; S G Kim; H Nakashima; N Yamamoto; K Sakamoto; S Yokoyama; H Takaku
Journal:  FEBS Lett       Date:  1993-09-13       Impact factor: 4.124

8.  The polypurine tract, PPT, of HIV as target for antisense and triple-helix-forming oligonucleotides.

Authors:  S Volkmann; J Dannull; K Moelling
Journal:  Biochimie       Date:  1993       Impact factor: 4.079

9.  In vitro effect of antisense oligonucleotides on human immunodeficiency virus type 1 reverse transcription.

Authors:  B Bordier; C Hélène; P J Barr; S Litvak; L Sarih-Cottin
Journal:  Nucleic Acids Res       Date:  1992-11-25       Impact factor: 16.971

10.  Inhibition of human telomerase activity by peptide nucleic acids.

Authors:  J C Norton; M A Piatyszek; W E Wright; J W Shay; D R Corey
Journal:  Nat Biotechnol       Date:  1996-05       Impact factor: 54.908

View more
  11 in total

Review 1.  Peptide nucleic acids: versatile tools for gene therapy strategies.

Authors:  D A Dean
Journal:  Adv Drug Deliv Rev       Date:  2000-11-15       Impact factor: 15.470

2.  Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression.

Authors:  B M Tyler; K Jansen; D J McCormick; C L Douglas; M Boules; J A Stewart; L Zhao; B Lacy; B Cusack; A Fauq; E Richelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 3.  PNA Technology.

Authors:  Peter E Nielsen
Journal:  Mol Biotechnol       Date:  2004-03       Impact factor: 2.695

4.  Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells.

Authors:  A F Faruqi; M Egholm; P M Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Nanoparticle for delivery of antisense γPNA oligomers targeting CCR5.

Authors:  Raman Bahal; Nicole Ali McNeer; Danith H Ly; W Mark Saltzman; Peter M Glazer
Journal:  Artif DNA PNA XNA       Date:  2013 Apr-Jun

Review 7.  Prospects for antisense peptide nucleic acid (PNA) therapies for HIV.

Authors:  Virendra N Pandey; Alok Upadhyay; Binay Chaubey
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

8.  miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates.

Authors:  Martin M Fabani; Michael J Gait
Journal:  RNA       Date:  2007-12-11       Impact factor: 4.942

9.  Borna disease virus glycoprotein is required for viral dissemination in neurons.

Authors:  Jeffrey J Bajramovic; Sylvia Münter; Sylvie Syan; Ulf Nehrbass; Michel Brahic; Daniel Gonzalez-Dunia
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 10.  Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics.

Authors:  Burak Berber; Cihan Aydin; Fatih Kocabas; Gulen Guney-Esken; Kaan Yilancioglu; Medine Karadag-Alpaslan; Mehmet Caliseki; Melek Yuce; Sevda Demir; Cihan Tastan
Journal:  Gene Ther       Date:  2020-12-14       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.